Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Prevalence and clinicopathological correlation of BRAF V600E mutations in ameloblastoma: A PCR study from a tertiary centre in South India.
Jayamani L et al.
Journal of Stomatology, Oral and Maxillofacial Surgery, 2025
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.
Ziegler M et al.
Jco Precision Oncology, 2025
Novel NRAS G12D mutation in extraosseous/peripheral ameloblastoma: Case report and review of mitogen-activated protein kinase pathway mutations in extraosseous/peripheral and intraosseous ameloblastomas.
Oh KY et al.
Journal of Dental Sciences, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J et al.
Nature Medicine, 2024
Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.
Kumbrink J et al.
Pathology Oncology Research : Por, 2024
Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas.
Pu X et al.
Cell & Bioscience, 2023
Postzygotic gain-of-function variants in FGFR2 in two patients with hair follicle naevus.
Cheng Q et al.
The British Journal of Dermatology, 2023
Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma.
Lawson-Michod KA et al.
Cancer Reports (hoboken, N.j.), 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D et al.
Nature, 2022
Cerebriform sebaceous nevus: a subtype of organoid nevus due to specific postzygotic FGFR2 mutations.
Theiler M et al.
Journal of the European Academy of Dermatology and Venereology : Jeadv, 2021
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer.
Servetto A et al.
Critical Reviews in Oncology/hematology, 2021
A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers.
Li J et al.
Frontiers in Oncology, 2021
The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors.
Guimarães LM et al.
Frontiers in Oral Health, 2021
Genetic Profile of Adenomatoid Odontogenic Tumor and Ameloblastoma. A Systematic Review.
Marín C et al.
Frontiers in Oral Health, 2021
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Chae YK et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2020
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L et al.
Nature Communications, 2019
Genomic landscape of salivary gland tumors.
Kato S et al.
Oncotarget, 2015
Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.
Gallo LH et al.
Cytokine & Growth Factor Reviews, 2015
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries.
Brown NA et al.
Biomarkers in Cancer, 2015
Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
Byron SA et al.
Plos One, 2012